Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to -$422.8 million.

  • Denali Therapeutics' Net Income towards Common Stockholders rose 4.01% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of -$422.8 million for FY2024, which is 191.12% down from last year.
  • According to the latest figures from FY2024, Denali Therapeutics' Net Income towards Common Stockholders is -$422.8 million, which was down 191.12% from -$145.2 million recorded in FY2023.
  • In the past 5 years, Denali Therapeutics' Net Income towards Common Stockholders ranged from a high of $71.1 million in FY2020 and a low of -$422.8 million during FY2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$326.0 million (2022), whereas its average is -$298.0 million.
  • In the last 5 years, Denali Therapeutics' Net Income towards Common Stockholders skyrocketed by 136.00% in 2020 and then crashed by 508.49% in 2021.
  • Over the past 5 years, Denali Therapeutics' Net Income towards Common Stockholders (Yearly) stood at $71.1 million in 2020, then crashed by 508.49% to -$290.6 million in 2021, then fell by 12.19% to -$326.0 million in 2022, then skyrocketed by 55.45% to -$145.2 million in 2023, then tumbled by 191.12% to -$422.8 million in 2024.